• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Keen Vision Acquisition Corporation

    1/6/26 9:33:27 PM ET
    $KVAC
    Get the next $KVAC alert in real time by email
    DEFA14A 1 ea0270550-05.htm DEFINITIVE ADDITIONAL MATERIALS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _____________________________________

    SCHEDULE 14A

    (Rule 14a)

    _____________________________________

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.    )

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material Under Rule 14a-12

    Keen Vision Acquisition Corporation

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    EXPLANATORY NOTE

    Keen Vision Acquisition Corporation (the “Company,” “we,” “our,” or “us”) is filing these definitive additional proxy materials with respect to the definitive proxy statement filed by the Company with the Securities and Exchange Commission (the “SEC”) on January 5, 2026 (the “Definitive Proxy Statement”), for the Annual General Meeting of Shareholders scheduled on January 22, 2026, in order to correct an inadvertent clerical error in the Definitive Proxy Statement regarding the proposed quarterly extension fee, which shall be $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”).

    All other information in the Definitive Proxy Statement remains unchanged.

     

    SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT

    The following disclosures should be read in conjunction with the disclosures contained in the Definitive Proxy Statement, which should be read in its entirety. To the extent the information set forth herein differs from or updates information contained in the Definitive Proxy Statement, the information set forth herein shall supersede or supplement the information in the Definitive Proxy Statement. The terms used below, unless otherwise defined, have the meanings set forth in the Definitive Proxy Statement.

    SUPPLEMENT NO. 1, DATED JANUARY 6, 2026

    (TO THE DEFINITIVE PROXY STATEMENT OF KEEN VISION ACQUISITION CORPORATION DATED JANUARY 5, 2026)

    SUPPLEMENT TO THE PROXY STATEMENT

    This supplement to the Definitive Proxy Statement (the “Supplement”), supplements, updates and amends the Definitive Proxy Statement of the Company filed with the SEC on January 5, 2026. The following supplemental information should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety.

    The Proposal 3 on the cover page of the Notice of Annual General Meeting of Shareholders is hereby amended and restated as follows:

    1. a proposal to amend the Company’s investment management trust agreement (the “Trust Agreement”), dated July 24, 2023, as amended on October 25, 2024 and July 23, 2025, entered into by the Company and Continental Stock Transfer & Trust Company, a New York limited liability trust company, as trustee (the “Trustee”), to provide the Company with the discretion to extend the date on which to commence liquidating the trust account (the “Trust Account”) established in connection with the Company’s initial public offering (the “IPO”) up to two additional times, each by a period of three months (the “Extension”), from January 27, 2026 to July 27, 2026 by depositing into the Trust Account an aggregate amount of $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”). The Trust Amendment is attached to the accompanying proxy statement as Annex A (the “Proposal 3” or “Trust Amendment Proposal”);

    The Proposal 3 on the cover page of the Proxy Statement is hereby amended and restated as follows:

    1. a proposal to amend the Company’s investment management trust agreement (the “Trust Agreement”), dated July 24, 2023, as amended on October 25, 2024 and July 23, 2025, entered into by the Company and Continental Stock Transfer & Trust Company, a New York limited liability trust company, as trustee (the “Trustee”), to provide the Company with the discretion to extend the date on which to commence liquidating the trust account (the “Trust Account”) established in connection with the Company’s initial public offering (the “IPO”) up to two additional times, each by a period of three months (the “Extension”), from January 27, 2026 to July 27, 2026 by depositing into the Trust Account an aggregate amount of $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”). The Trust Amendment is attached to the accompanying proxy statement as Annex A (the “Proposal 3” or “Trust Amendment Proposal”);

     

    The second Q&A on page 1 of the Definitive Proxy Statement is hereby amended and restated as follows:

    Q. What is being voted on?

     

    A.

     

    You are being asked to consider and vote on the following proposals:

           

    •   a proposal to elect five directors to serve as members of the Board of Directors to hold office until the next annual meeting of shareholders or until their respective successors have been elected and qualified (the “Proposal 1” or the “Election of Directors Proposal”);

    •   a proposal to ratify the appointment of Adeptus Partners, LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (the “Proposal 2” or the “Auditor Appointment Ratification Proposal”);

    •   a proposal to amend the Company’s investment management trust agreement (the “Trust Agreement”), dated July 24, 2023, as amended on October 25, 2024 and July 23, 2025, entered into by the Company and Continental Stock Transfer & Trust Company, a New York limited liability trust company, as trustee (the “Trustee”), to provide the Company with the discretion to extend the date on which to commence liquidating the trust account (the “Trust Account”) established in connection with the Company’s initial public offering (the “IPO”) up to two additional times, each by a period of three months (the “Extension”), from January 27, 2026 to July 27, 2026 by depositing into the Trust Account $120,000 for each of three-month extension for all remaining public shares (the “Extension Payment”). The Trust Amendment is attached hereto as Annex A (the “Proposal 3” or “Trust Amendment Proposal”);

    •   a proposal to amend the Company’s third amended and restated memorandum and articles of association as adopted by resolution of shareholder passed on July 22, 2025 and filed on July 24, 2025 (the “Amended and Restated Memorandum and Articles of Association”) to extend the date by which the Company must consummate a business combination to July 27, 2026 (the “Extended Date”), by adopting the fourth amended and restated memorandum and articles of association (the “Fourth Restated Memorandum and Articles”) in their entirety in place of the Company’s existing Amended and Restated Memorandum and Articles of Association, the form of which is set forth in Annex B attached hereto (the “Proposal 4” or “Charter Amendment Proposal”); and

    •   a proposal to direct the chairman of the Annual General Meeting to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Annual General Meeting, there are not sufficient votes to approve the Trust Amendment Proposal (the “Proposal 5” or the “Adjournment Proposal”).

     

    The sixth paragraph on page Annex A-1 is hereby amended and restated as follows:

    “WHEREAS, as described Registration Statement and in its Amended and Restated Memorandum and Articles of Association, the Company’s ability to complete a business combination may be extended two times for an additional three months each time from January 27, 2026 to July 27, 2026, subject to the payment into the Trust Account by the Sponsor (or its designees or affiliates) of $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”), and which Extension Payments, if any, shall be added to the Trust Account.”

    Trust Amendment Proposal on the proxy card is hereby amended and restated as follows:

    PROPOSAL 3: Trust Amendment Proposal.

    As an resolution of members, to amend the Company’s investment management trust agreement, dated July 24, 2023 entered into by the Company and Continental Stock Transfer & Trust Company, a New York limited liability trust company, as trustee, to provide the Company with the discretion to extend the date on which to commence liquidating the trust account established in connection with the Company’s initial public offering (the “Trust Account”) up to two additional times, each by a period of three months, from January 27, 2026 to July 27, 2026 by depositing into the Trust Account $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”). The Trust Amendment is attached to the accompanying proxy statement as Annex A.

    For

     

    Against

     

    Abstain

    ☐

     

    ☐

     

    ☐

    ******

    If you would like to change or revoke your prior vote on any proposal, please submit your votes before 11:59 pm ET January 21, 2026. In addition, shareholders who have already submitted a redemption request with respect to the shares held by them may reverse such request by contacting Continental Stock Transfer & Trust Company. Email: [email protected]. If you would like to change or revoke your prior vote on any proposal, or reverse a redemption request, please refer to the Definitive Proxy Statement for additional information on how to do so.

    This Supplement should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety. Except as specifically amended by this Supplement, all information in the Definitive Proxy Statement remains unchanged and the Definitive Proxy Statement continues to be in full force and effect as originally filed. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Definitive Proxy Statement as amended and supplemented by this Supplement. If you have already submitted a proxy and do not wish to change your vote, you need not take any further action. If you have submitted a proxy and wish to change your vote, you may revoke your proxy at any time before it is exercised at the Annual General Meeting by: delivering to Advantage Proxy, Inc. by mail a written notice stating that the proxy is revoked; signing and delivering a proxy bearing a later date; voting again online; or voting at the Annual General Meeting while the polls are open (note that attendance at the Annual General Meeting will not, by itself, revoke a proxy unless you vote again electronically at the Annual General Meeting). Please note, however, that if your shares are held in street name by a broker or other nominee and you wish to revoke a proxy, you must contact the broker or nominee to revoke any prior voting instructions.

    This Proxy Supplement is dated January 6, 2026

     

    PROXY CARD

    KEEN VISION ACQUISITION CORPORATION

    37 Greenbriar Drive

    Summit, New Jersey 07901

    (203) 609-1394

    ANNUAL MEETING OF SHAREHOLDERS

    JANUARY 22, 2026

    YOUR VOTE IS IMPORTANT

    FOLD AND DETACH HERE

    THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2026

    The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice and Proxy Statement, dated January 5, 2026, in connection with the Annual General Meeting and at any adjournments thereof (the “Annual General Meeting”) to be held at 10:00 am Eastern Time on January 22, 2026 in Hong Kong and hereby appoints WONG, Kenneth Ka Chun and DAVIDKHANIAN, Alex, and each of them (with full power to act alone), the attorneys and proxies of the undersigned, with power of substitution to each, to vote all ordinary shares of Keen Vision Acquisition Corporation (the “Company”) registered in the name provided, which the undersigned is entitled to vote at the Annual General Meeting with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxies are, and each of them is, instructed to vote or act as follows on the proposals set forth in this Proxy Statement.

    THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” PROPOSAL 1 AND “FOR” PROPOSAL 2.

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR ALL” PROPOSAL 1 AND “FOR” PROPOSAL 2, 3, 4 and 5.

    PROPOSAL 1: Election of Directors

    As a resolution of members, to approve the appointment of five (5) members to the Board of Directors.

    NOMINEES:

    WONG, Kenneth Ka Chun

     

    DAVIDKHANIAN, Alex

     

    DING, Yibing Peter

     

    CHU, William

     

    Professor YU, Albert Cheung-Hoi, Ph.D., J.P.

    For All

         

    Withhold All

     

    For All Except

    ☐

         

    ☐

     

    ☐

    INSTRUCTION:

     

    To withhold authority to vote for any individual nominee(s), mark “FOR ALL EXCEPT” and fill in the box next to each nominee you wish to withhold, as shown here:

             
       

     

       
             
       

     

       
             
       

     

       

     

    PROPOSAL 2: Ratification of Appointment of Independent Auditor

    As a resolution of members, to ratify the appointment of ADEPTUS PARTNERS, LLC as the Company’s independent registered public account firm for the 2025 fiscal year.

    For

         

    Against

     

    Abstain

    ☐

         

    ☐

     

    ☐

    PROPOSAL 3: Trust Amendment Proposal.

    As an resolution of members, to amend the Company’s investment management trust agreement, dated July 24, 2023 entered into by the Company and Continental Stock Transfer & Trust Company, a New York limited liability trust company, as trustee, to provide the Company with the discretion to extend the date on which to commence liquidating the trust account established in connection with the Company’s initial public offering (the “Trust Account”) up to two additional times, each by a period of three months, from January 27, 2026 to July 27, 2026 by depositing into the Trust Account $120,000 for each three-month extension for all remaining public shares (the “Extension Payment”). The Trust Amendment is attached to the accompanying proxy statement as Annex A.

    For

         

    Against

     

    Abstain

    ☐

         

    ☐

     

    ☐

    PROPOSAL 4: Charter Amendment Proposal.

    As a resolution of members, to amend the Company’s third amended and restated memorandum and articles of association as adopted by resolution of shareholder passed on July 22, 2025 and filed on July 24, 2025 (the “Amended and Restated Memorandum and Articles”), to extend the date by which the Company must consummate a business combination to July 27, 2026, by adopting the fourth amended and restated memorandum and articles of association (the “Fourth Restated Memorandum and Articles”) in their entirety in place of the Company’s current Amended and Restated Memorandum and Articles), the form of which is set forth in Annex B of the accompanying proxy statement.

    For

         

    Against

     

    Abstain

    ☐

         

    ☐

     

    ☐

    PROPOSAL 5: Adjournment Proposal

    As a resolution of members, to direct the chairman of the Annual General Meeting to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Annual General Meeting, there are not sufficient votes to approve the Proposals 1, 2, 3 and 4.

    For

         

    Against

     

    Abstain

    ☐

         

    ☐

     

    ☐

    Please indicate if you intend to attend this Meeting            ☐ YES            ☐ NO

    Signature of Shareholder:

         

     

    Date:

         

     

    Name shares held in (Please print):

         

    Account Number (if any):

     

         

     

    No. of Shares Entitled to Vote:

         

    Stock Certificate Number(s):

     

         

     

     

    Note:

     

    Please sign exactly as your name or names appear in the Company’s stock transfer books. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such.

     

    If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such.

    If the signer is a partnership, please sign in partnership name by authorized person.

    Please provide any change of address information in the spaces below in order that we may update our records:

    Address:

     

     

       

     

       

    Shareholder’s Signature

    Shareholder’s Signature

    Signature should agree with name printed hereon. If stock is held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney.

    PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY. THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” THE PROPOSALS SET FORTH IN PROPOSALS 1 AND 2 AND WILL GRANT DISCRETIONARY AUTHORITY TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE ANNUAL GENERAL MEETING OR ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU.

    PLEASE COMPLETE, DATE, SIGN AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.

     

    Get the next $KVAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medera's Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

    First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapiesLeveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical com

    6/24/25 8:00:00 AM ET
    $KVAC

    Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA. Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFp

    4/1/25 8:00:00 AM ET
    $KVAC

    Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

    BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3

    3/20/25 8:00:00 AM ET
    $KVAC

    $KVAC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Keen Vision Acquisition Corporation

    DEFA14A - Keen Vision Acquisition Corp. (0001889983) (Filer)

    1/6/26 9:33:27 PM ET
    $KVAC

    SEC Form DEF 14A filed by Keen Vision Acquisition Corporation

    DEF 14A - Keen Vision Acquisition Corp. (0001889983) (Filer)

    1/5/26 5:01:42 PM ET
    $KVAC

    Keen Vision Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)

    1/5/26 4:05:27 PM ET
    $KVAC

    $KVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Keen Vision Acquisition Corporation

    SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/14/24 9:07:56 PM ET
    $KVAC

    SEC Form SC 13G filed by Keen Vision Acquisition Corporation

    SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/14/24 6:03:06 PM ET
    $KVAC

    Amendment: SEC Form SC 13G/A filed by Keen Vision Acquisition Corporation

    SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

    11/12/24 4:07:50 PM ET
    $KVAC